Luteal Phase Administration of Paroxetine for the Treatment of PMDD

Phase 3CompletedNCT00620581

Hamilton Health Sciences Corporation

Overview

The efficacy of SSRI use to relieve the symptoms associated with premenstrual dysphoric disorder has been established. We proposed to test the hypothesis that intermittent treatment with paroxetine administered during the luteal phase of the menstrual cycle only is more effective than placebo in improving symptoms of PMDD. This was a double-blind, placebo-controlled, three-arm parallel group study of patients with PMDD. Menstruating women 18 years of age or older who met criteria for inclusion in the study were randomized to one of three arms: paroxetine 10mg/day during the luteal phase of the menstrual cycle; paroxetine 20mg/day during the luteal phase of the menstrual cycle; placebo daily during the luteal phase of the menstrual cycle. The objective was to evaluate the efficacy and safety of intermittent treatment of paroxetine in women with PMDD.

Study Type

INTERVENTIONAL

Conditions

Premenstrual Dysphoric Disorder

Interventions

ParoxetineDRUG

Paroxetine 10mg and 20mg during the luteal phase of the menstrual cycle

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: * PMDD according to DSM-IV criteria Exclusion Criteria: * Women were excluded if they were taking oral contraception, breast-feeding, pregnant, or planning to become pregnant during the study period. * Women were also excluded if they met DSM-IV criteria for any Axis I disorder, were deemed a suicidal risk, had a history of SSRI use for premenstrual symptoms, were taking ongoing medication that could affect PMDD symptoms, had a clinically significant abnormality on screening blood tests, or had a baseline Montgomery-Asberg Depression Rating Scale score of equal to or greater than 10 during the follicular phase of the menstrual cycle.

Locations (1)

Women's Health Concerns Clinic

Hamilton, Ontario, Canada

Outcomes

Primary Outcomes

Visual Analogue Scales

Secondary Outcomes

PMTS-O; CGI-S; Sheehan Disability Scale

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.